Title: NEEDLE-FREE INJECTIONS IN A CONNECTED WORLD

Biography:

Dr. Patrick Anquetil is Portal Instrument’s Chief Executive Officer. He brings more than 20 years of experience building world-class teams and leading high-tech / tough-tech bioengineering companies from the lab to the marketplace. Prior to founding Portal, he was co-founder of SynapDx, an autism diagnostic company based on RNA expression analysis, and Aretais, a venture in the field of blood glucose monitoring leveraging advances in Coherent Anti-stokes Raman Spectroscopy. Dr. Anquetil began his career as a science and nanotechnology equity research analyst at Susquehanna International Group authoring and marketing equity research reports to hedge funds and portfolio managers. Dr. Anquetil holds a doctorate in bio-instrumentation from MIT, an MBA from Harvard Business School, and a master's degree from the ETH in Zurich and the University of Tokyo. His scientific work has appeared in peer-reviewed publications as well as mainstream media, including MIT Technology Review, Wired Magazine, PBS, and CNBC.

Abstract

Adherence to treatment in injectable therapies for chronic disease is very low (45% - 60%) and in part due to the inconvenience and anxiety of using needles. There is an opportunity for a new form of drug delivery system that is needle-free to change this situation and transform the perception and approachability of therapies based on injectable biologics. Portal Instruments has developed a computer-controlled needle-free system transforming this paradigm and empowering patients to self-inject their medicines with an easy to use and approachable device. This innovative drug delivery system replaces needle & syringes and auto-injectors and clinical studies have demonstrated that it is well tolerated. Issued from MIT Research and easily connected to the cloud, the Portal device allows biopharmaceutical companies to augment their biological injectable therapies and offer a modern administration method for patients. The device captures injection data in real time and keeps all stakeholders involved for optimal care. Clinical and market studies have shown that patients prefer the Portal Needle-free injector device vs. traditional needle and syringe injections and would be willing to switch therapies if drugs were available with this device.